Evan Seigerman
Stock Analyst at BMO Capital
(3.84)
# 678
Out of 4,944 analysts
146
Total ratings
51.04%
Success rate
8.94%
Average return
Main Sectors:
Stocks Rated by Evan Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $557 → $530 | $395.92 | +33.87% | 16 | Aug 5, 2025 | |
| INCY Incyte | Maintains: Underperform | $52 → $60 | $85.85 | -30.11% | 13 | Jul 30, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $112 → $120 | $61.10 | +96.40% | 6 | May 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $96 → $115 | $131.62 | -12.63% | 15 | May 6, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $115 → $120 | $120.14 | -0.12% | 17 | Apr 17, 2025 | |
| BIIB Biogen | Maintains: Market Perform | $156 → $139 | $135.19 | +2.82% | 27 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Market Perform | $57 → $61 | $47.85 | +27.48% | 11 | Nov 12, 2024 | |
| LLY Eli Lilly and Company | Maintains: Outperform | $1,001 → $1,101 | $660.49 | +66.69% | 8 | Aug 9, 2024 | |
| GPCR Structure Therapeutics | Initiates: Outperform | $40 | $19.16 | +108.77% | 1 | Feb 28, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $40 | $5.09 | +685.85% | 1 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $757 → $788 | $561.55 | +40.33% | 17 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $8 → $2.5 | $2.61 | -4.21% | 2 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $263 → $243 | $289.33 | -16.01% | 6 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $6.40 | +87.50% | 2 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $25.16 | +138.47% | 1 | Nov 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $30 | $1.66 | +1,707.23% | 3 | May 12, 2020 |
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Outperform
Price Target: $557 → $530
Current: $395.92
Upside: +33.87%
Incyte
Jul 30, 2025
Maintains: Underperform
Price Target: $52 → $60
Current: $85.85
Upside: -30.11%
Disc Medicine
May 12, 2025
Maintains: Outperform
Price Target: $112 → $120
Current: $61.10
Upside: +96.40%
Neurocrine Biosciences
May 6, 2025
Maintains: Market Perform
Price Target: $96 → $115
Current: $131.62
Upside: -12.63%
Gilead Sciences
Apr 17, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $120.14
Upside: -0.12%
Biogen
Feb 13, 2025
Maintains: Market Perform
Price Target: $156 → $139
Current: $135.19
Upside: +2.82%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Market Perform
Price Target: $57 → $61
Current: $47.85
Upside: +27.48%
Eli Lilly and Company
Aug 9, 2024
Maintains: Outperform
Price Target: $1,001 → $1,101
Current: $660.49
Upside: +66.69%
Structure Therapeutics
Feb 28, 2023
Initiates: Outperform
Price Target: $40
Current: $19.16
Upside: +108.77%
Replimune Group
Oct 14, 2022
Maintains: Outperform
Price Target: $30 → $40
Current: $5.09
Upside: +685.85%
Aug 4, 2022
Maintains: Outperform
Price Target: $757 → $788
Current: $561.55
Upside: +40.33%
Aug 2, 2022
Downgrades: Market Perform
Price Target: $8 → $2.5
Current: $2.61
Upside: -4.21%
Apr 28, 2022
Maintains: Market Perform
Price Target: $263 → $243
Current: $289.33
Upside: -16.01%
Mar 31, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $6.40
Upside: +87.50%
Nov 19, 2021
Initiates: Outperform
Price Target: $60
Current: $25.16
Upside: +138.47%
May 12, 2020
Maintains: Outperform
Price Target: $13 → $30
Current: $1.66
Upside: +1,707.23%